The cost-effectiveness of extended-release calcifediol versus paricalcitol for the treatment of secondary hyperparathyroidism in stage 3-4 CKD.
CONCLUSIONS: This model demonstrated favorable short- and long-term clinical benefits associated with the use of ERC in patients with CKD Stage 3 and 4 with SHPT and VDI, suggesting ERC may be cost-effective from the Medicare perspective compared to paricalcitol.
PMID: 31726882 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - Category: Health Management Tags: J Med Econ Source Type: research
More News: Cardiology | Cardiovascular | Chronic Kidney Disease | Dialysis | Economics | Health Management | Heart | Hyperparathyroidism | Medicare | Orthopaedics | Study | Urology & Nephrology | USA Health | Vitamin D | Vitamins